?? Our founder and CEO Syam Palakurthy shares impactful insights on Optum's decision to drop #reauthorizations for critical #MS, #migraine, and #highcholesterol drugs. Be sure to check out his post for important context on this recent announcement! #patientaccess #priorauthorization #optum #utilizationmanagement #data #neurology #cardiology #infusions
This will be a really good thing for patients and doctors if Optum does indeed get rid of more renewal PAs (and if more payers follow!). Frankly, it'd be good for payers as well: https://lnkd.in/gRhYsTVp We looked at a sample of these drugs in our data, and found approval rate of 74% for initiation PAs compared to 91.5% of the time for renewals. I happen to believe both approval numbers are still too low relative to the clinical validity, but it's especially hard to justify forcing a doc and a patient through this extremely painful process for a drug that is a.)working for the patient and b.) getting approved the vast majority of the time anyways.